stockrowICON PLC
ICLR Healthcare Diagnostics & Research
ICON PLC’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.76% from fiscal 2024.
- Revenue
- −2.86%
- EPS
- +143.2%
- Free cash flow
- −8.01%
- Total debt
- −0.86%
Quarter to September 2026, against a year earlier
Follow ICLR
Alert me
ICON PLC (ICLR) Return on equity
ICON PLC's return on equity over the twelve months to 30 September 2026 was 4.86%, up 2.4 percentage points from fiscal 2025 (2.46%). Over the past ten years it has ranged from 2.46% (fiscal 2025) to 30.7% (fiscal 2016) — the current reading is the lowest in ten years. That is above the Diagnostics & Research industry median of 0.00% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 2.46% | (5.45) |
| FY2024 | 7.91% | 1.01 |
| FY2023 | 6.90% | 0.80 |
| FY2022 | 6.10% | 3.01 |
| FY2021 | 3.09% | (15.86) |
| FY2020 | 19.0% | (5.88) |
| FY2019 | 24.8% | (0.52) |
| FY2018 | 25.4% | (1.00) |
| FY2017 | 26.4% | (4.35) |
| FY2016 | 30.7% | 2.74 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| GH Guardant Health, Inc. compare | 153.9% |
| MEDP Medpace Holdings, Inc. compare | 117.9% |
| ILMN Illumina, Inc. compare | 32.4% |
| DGX Quest Diagnostics Incorporated compare | 14.8% |
| QGEN QIAGEN N.V. compare | 11.9% |
| LH Labcorp Holdings Inc. compare | 11.5% |
| ICLR ICON PLC | 4.86% |
| CRL Charles River Laboratories International, Inc. compare | 1.21% |
| RVTY Revvity Inc. compare | 0.00% |
| Diagnostics & Research industry median | 0.00% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on ICLR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement